Soliris® (eculizumab) 300 mg (10 mg/mL) Intravenous (IV) Infusion.
SOLIRIS (eculizumab) MB9938
Myasthenia gravis: Historical achievements and the “golden age” of clinical trials - ScienceDirect
ALEXION PHARMACEUTICALS, INC.
Brain Sciences | Free Full-Text | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
Alexion: download vector logo and get Alexion Pharmaceuticals brand information and colors.
Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
Soliris® (eculizumab)
Preventing meningococcal disease in patients receiving Soliris
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
Soliris® (eculizumab)
Brain Sciences | Free Full-Text | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
SOLIRIS® (ECULIZUMAB)
Form 10-K
SPECIALTY GUIDELINE MANAGEMENT
Initial Criteria:
CONCLUSIONS ACKNOWLEDGMENTS DISCLOSURES REFERENCES James F. Howard, Jr,1 Richard J. Nowak,2 Gil I. Wolfe,3 Michael G. Benatar,4
SPECIALTY GUIDELINE MANAGEMENT
SOLIRIS® (eculizumab) HCP | MOA
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2) (NASDAQ:ALXN) | Seeking Alpha
g993172.jpg
Soliris® (eculizumab) | Alexion
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study
